Experience

• Healthcare & Life Sciences

  • The George Robert Rawlings Trust in the sale of the Rawlings Companies to New Mountain Capital Group L.P.
  • Konica Minolta, a Japanese multinational equipment and materials manufacturer operating in the healthcare and industrial industries, in the sale of its subsidiary Invicro to Calyx, a portfolio company of CapVest and leading technology-enabled provider.
  • Guggenheim Securities, as financial advisor to Gilead, in Gilead's $4.3 billion acquisition of biopharmaceutical company CymaBay.
  • Sawai and Sumitomo in the $210 million sale of its subsidiary Upsher-Smith Laboratories to Bora Pharmaceuticals.
  • Tarsadia Investments in the reorganization of Amneal Pharmaceuticals, a global pharmaceuticals company with a diverse portfolio of approximately 270 pharmaceutical products, which includes eliminating its umbrella partnership-C-corporation structure.
  • J.P. Morgan Securities, as financial advisor to Olink, in the sale of Olink to Thermo Fisher, valuing Olink at $3.1 billion.
  • TPG in its acquisition of a majority interest in OneOncology, a network of leading oncology practices, in a transaction valued at $2.1 billion.
  • Gentiva, a Clayton, Dubilier & Rice portfolio company and leading hospice, palliative, and personal care company, in its acquisition of Heartland hospice and home care.
  • Gedeon Richter, the specialty pharmaceutical company, in its acquisition of OC Distributors, an Ireland-based company holding the marketing and distribution rights of a number of women’s healthcare products.
  • J.P. Morgan Securities, as co-financial advisor to Horizon Therapeutics, a global biotechnology company, in its $28.5 billion sale to Amgen.
  • Deutsche Bank as financial advisor to Signify Health, a leading health care platform, in its $8 billion sale to CVS Health, a leading health solutions company.
  • Clayton, Dubilier & Rice and TPG in their $4 billion take-private of Covetrus, a global animal-health technology and services company.
  • Kindred Healthcare, a TPG portfolio company and leading specialty hospital company delivering acute health services, in its sale to LifePoint Health, a leader in the delivery of community-based care.
  • Evercore and Guggenheim Securities as financial advisors to Arena, a clinical stage pharmaceuticals company, in its sale to Pfizer for a total equity value of approximately $6.7 billion.
  • A major investor in Envigo, a pharmaceutical and biotechnology research provider, in the sale of Envigo to Inotiv, a drug discovery and development contract research organization, for a total transaction value of approximately $545 million.
  • Allergan in its sale of Brazikumab to AstraZeneca and Zenpep to Nestle.
  • J.P. Morgan Securities, as financial advisor to PPD, in PPD's sale to Thermo Fisher for $17.4 billion in cash plus $3.5 billion of net debt.
  • Kindred Healthcare in the sale of its RehabCare business line, a provider of contract therapy services in 43 states, to Select Rehabilitation, a leading provider of contract rehabilitation services.
  • Johnson & Johnson in its acquisition from AstraZeneca of the global rights outside of the U.S. to Rhinocort Aqua, a line of nasal sprays used to treat allergies.
  • Perella Weinberg, as financial advisor to HealthEquity, in HealthEquity’s acquisition of Further for $500 million.
  • J.P. Morgan Securities, as financial advisor to AmerisourceBergen, in AmerisourceBergen’s acquisition of Alliance Healthcare from Walgreens Boots Alliance for approximately $6.5 billion in cash and stock.
  • TPG, Welsh, Carson, Anderson & Stowe and Kindred at Home in the sale of Kindred at Home to Humana, valuing Kindred at Home at $8.1 billion.
  • Centerbridge Partners in its investment in GoHealth.
  • J.P. Morgan Securities, as financial advisor to Allergan, in the sale of Allergan to AbbVie for $63 billion in cash and stock.
  • Sawai Pharmaceutical in the sale of a minority stake of its U.S. subsidiary, Upsher-Smith Laboratories, to Japanese trading house Sumitomo.
  • Nestlé Skin Health in its $1 billion acquisition of Guthy Renker’s worldwide Proactiv business, the world’s leading non-prescription acne brand.
  • Prudential Financial in its $2.35 billion acquisition of Assurance IQ.
  • TPG Growth in its takeover of the existing assets of the Abraaj Group’s $1 billion Global Healthcare Fund. The deal saw Debevoise win the Specialist Deal Legal Advisor category at the Private Equity Africa Awards.
  • Sawai Pharmaceutical in its $1.5 billion acquisition of the generic pharmaceuticals business of Upsher-Smith Laboratories.
  • Guggenheim Securities and Morgan Stanley, as financial advisors to Pfizer, in its $11.4 billion acquisition of Array Biopharma.
  • Allergan in its $639 million acquisition of Vitae Pharmaceuticals, a clinical-stage biotechnology company.
  • Deutsche Bank Securities, as financial advisor to Eli Lilly, in Eli Lilly's $8 billion acquisition of Loxo Oncology.
  • TPG in the sale of Adare Pharmaceuticals, a leading specialty contract development and manufacturing organization, to Thomas H. Lee Partners and Frazier Healthcare Partners and the related separation of Adare’s Eosinophilic Esophagitis product into a TPG-backed entity.
  • J.P. Morgan Securities, as financial advisor to The Medicines Co., in the $9.7 billion acquisition of The Medicines Co. by Novartis AG.
  • Guggenheim Securities and J.P. Morgan Securities, as financial advisors to Bioverativ, a global biopharmaceutical company, in Bioverativ’s $11.6 billion sale to Sanofi.
  • Deutsche Bank Securities, as financial advisor to Mallinckrodt, in Mallinckrodt's $1.2 billion acquisition of Sucampo Pharmaceuticals.
  • TPG and Welsh, Carson, Anderson & Stowe in the $4.1 billion acquisition of Kindred Healthcare.
  • Allergan in its $2.9 billion acquisition of LifeCell Corporation, a regenerative medicine business.
  • Lannett in its acquisition for $1.23 billion in cash, plus additional contingent consideration, of Kremers Urban Pharmaceuticals, the U.S. specialty generic pharmaceuticals subsidiary of global biopharmaceuticals company UCB.
  • TPG and Welsh, Carson, Anderson & Stowe, with Humana, in their $1.4 billion acquisition of Curo Health Services.
  • Misys in the combination of its healthcare business with Allscripts Healthcare Solutions, resulting in Misys owning a 54.5% interest in Allscripts-Misys Healthcare Solutions.
  • Allergan in its $2.47 billion acquisition of ZELTIQ, a medical technology company focused on utilizing its proprietary CoolSculpting controlled-cooling technology platform, the sales leader in the fast-growing body contouring segment of medical aesthetics.
  • Clayton, Dubilier & Rice in the formation of agilon health, a new healthcare technology and services platform, through the acquisition and merging of Primary Provider Management and Cyber-Pro Systems.
  • Clayton, Dubilier & Rice in its acquisition of a controlling stake in Drive DeVilbiss Healthcare, a leading global manufacturer of medical products.
  • Noven Pharmaceuticals in the sale of its Brisdelle and Pexeva product lines to Sebela International.
  • Envision Healthcare in its $620 million acquisition of Rural/Metro Corporation, the second largest provider of ambulatory services in the U.S.
  • Ally Bridge in its PIPEs transaction with Nasdaq-listed Sorrento Therapeutics, a U.S. biotechnology company.
  • Allergan in its global collaboration agreement with AstraZeneca to develop and commercialize ATM-AVI, an investigational, fixed-dose antibiotic.
  • Actavis in the sale of its branded respiratory business in the U.S. and Canada to AstraZeneca for $600 million, and an additional payment of $100 million relating to certain other agreements.
  • J.P. Morgan Securities, as financial advisor to Salix Pharmaceuticals, in the $15.8 billion sale of Salix Pharmaceuticals to Valeant Pharmaceuticals.
  • Actavis in the sale of Aptalis Pharmaceutical Technologies, a pharmaceutical outsourcing and R&D business in the U.S., to TPG.
  • Morgan Stanley, as financial advisor to NASDAQ-listed life science and technology company Sigma-Aldrich, in the $17 billion acquisition of Sigma-Aldrich by Merck KGaA.
  • Actavis in its acquisition of Nasdaq-listed Durata Therapeutics, a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses, for $675 million plus contingent value rights.
  • Stone Point Capital in its sale of Genex, a provider of healthcare and disability management services, to Apax Partners.
  • Diamond Castle in the acquisition by its portfolio company Beacon Health of ValueOptions, the largest independent behavioral healthcare and wellness company in the U.S.
  • Clayton, Dubilier & Rice in its $910 million acquisition of Healogics, the largest advanced wound care services provider in the U.S.
  • Forest Laboratories in its $2.9 billion acquisition of Aptalis, a gastrointestinal and cystic fibrosis company, from TPG.
  • Noven Pharmaceuticals in its acquisition from Novartis of the commercial rights to Minivelle, an estradiol transdermal system, in the U.S. and Canada.
  • Guggenheim Securities, as financial advisor to Pfizer, in Pfizer's $2.38 billion sale of Capsugel, a leading maker of hard capsule and other drug-delivery systems, to Kohlberg Kravis Roberts.
  • Forest Laboratories in its acquisition of the Colistin business of Grünenthal GmbH.
  • Misys in its $915 million acquisition of Medic Computer Systems.
  • Gen-Probe in its collaboration agreement with Pacific Biosciences of California in the research and development of third-generation DNA testing systems for use in disease diagnosis and blood screening.
  • An investor in the $113 million taking private of a pre-clinical trial company.
  • Lehman Brothers in numerous financial advisory assignments, including Thermo Electron’s $10.6 billion acquisition of Fisher Scientific Industries to create Thermo Fisher Scientific, and Medco Health Solutions’ $2.3 billion acquisition of Accredo Health, creating the largest specialty pharmacy business in the U.S.
  • North Castle Partners in the $650 million recapitalization of Leiner Health Products.

• Other

  • J.P. Morgan Securities, as financial advisor to the special committee of Franklin BSP Lending Corporation (FBLC), in FBLC’s merger with Franklin BSP Capital Corp.
  • Deutsche Bank, as financial advisor to Bottomline Technologies, a financial technology provider, in its sale to Thoma Bravo, valued at approximately $2.6 billion.
  • Third Point Re in its $788 million merger with Sirius Group.
  • Morgan Stanley, as financial advisor to Citizens Financial, in Citizens Financial’s acquisition of all of the outstanding shares of Investors Bancorp in a stock and cash deal for approximately $3.5 billion.
  • Prudential plc and Jackson National in the reinsurance to Athene of $27.6 billion of Jackson’s in-force fixed and fixed index annuities and a $500 million equity investment in Jackson’s holding company.
  • Deutsche Bank Securities, as financial advisor to Trinseo, in the $491 million sale of Trinseo’s synthetic rubber business to Synthos.
  • P2 Capital, alongside Silver Lake, in the $3.5 billion acquisition of Blackhawk, a global financial technology company.
  • Hussmann, a Clayton, Dubilier & Rice portfolio company, in its $1.5 billion sale to Panasonic.
  • Credit Suisse, as financial advisor to JACK Entertainment, in the $780 million sale of JACK Cincinnati Casino and Turfway Park to Hard Rock International and VICI Properties.
  • Deutsche Bank Securities, as financial advisor to Bally’s, in Bally’s combination with Gamesys.
  • American Securities and P2 Capital Partners in their $855 million acquisition of Blount International.
  • Deutsche Bank Securities, as financial advisor to Front Yard, in the $2.4 billion sale of Front Yard to Pretium and Ares Management.
  • J.P. Morgan Securities, as financial advisor to CommScope, in CommScope's $7.4 billion acquisition of ARRIS.
  • American International Group in several transactions with Fairfax Financial, a leading global property and casualty insurer and reinsurer, as part of a strategic partnership in 12 jurisdictions across Latin America, Central and Eastern Europe.
  • J.P. Morgan Securities, as financial advisor to FS Investment Corporation, in FS Investment Corporation's $8 billion merger with Corporate Capital Trust.
  • Deutsche Bank Securities, as financial advisor to Invitation Homes, in Invitation Homes's $20 billion merger with Starwood Waypoint Homes.
  • Clayton, Dubilier & Rice in its acquisitions of Brand Energy and Harsco Infrastructure in a combined transaction valued at $2.5 billion.
  • J.P. Morgan Securities and Morgan Stanley, as financial advisors to American International Group, in its $3.4 billion sale of United Guaranty Corporation, the leading private mortgage insurance company in the United States, to Arch Capital Group.
  • MBIA in its sale of Cutwater Asset Management, an investment management company with $23 billion in assets under management, to BNY Mellon.
  • J.P. Morgan Securities, as financial advisor to Walmart, in Walmart's $3.3 billion acquisition of Jet.com.
  • P2 Capital, with Goldman Sachs Capital Partners, in its $1.6 billion sale of Interline Brands to Home Depot.
  • NCI Building Systems in its acquisition of Metl-Span, a leading insulated panel supplier.
  • Deutsche Bank Securities, as financial advisor to Marriott International, in Marriott International's $12.2 billion acquisition of Starwood Hotels and Resorts Worldwide.
  • Atkore International in its redemption of Tyco International’s minority investment in Atkore’s parent company, Atkore International Group.
  • Morgan Stanley and Zaoui & Co., as financial advisors to NYSE-listed oil-equipment maker Dresser-Rand Group, in the $7.6 billion acquisition of Dresser-Rand by Siemens.
  • American International Group in the $7.6 billion sale of its 100% interest in International Lease Finance Corporation to NYSE-listed AerCap Holdings N.V.
  • Highland Capital Management in its sale of Communications Corporation of America and White Knight Broadcasting to Nexstar Broadcasting Group and Mission Broadcasting.
  • Highland Capital Management, Contrarian, J.P. Morgan and Black Diamond Capital Management in Clean Harbors' $1.25 billion acquisition of Safety-Kleen.
  • P2 Capital Partners in its $1.1 billion take-private acquisition, together with funds managed by the private equity arm of Goldman Sachs, of Interline Brands, a leading distributor of broad-line maintenance, repair and operations products.
  • Prudential Financial in its sale of Afore XXI, a Mexican private pension manager, to Banorte.
  • Prudential Financial in its $4.5 billion sale of a noncontrolling interest in its joint brokerage venture, Wells Fargo Advisors, to Wells Fargo.
  • NCI Building Systems in its $245 million acquisition of CENTRIA.
  • Morgan Stanley, as financial advisor to The Pepsi Bottling Group, in the $7.8 billion acquisition of The Pepsi Bottling Group by PepsiCo.
  • HarbourVest Partners in its acquisition of the Lehman Brothers Venture Partners business.
  • EDO Corporation in its $1.7 billion acquisition by ITT Corporation.
  • Babcock & Brown in its $1.33 billion acquisition of Coinmach, a leading supplier of outsourced laundry equipment services.
  • Bairnco in the acquisition by Steel Partners II of all of the Bairnco stock that it did not already own.
  • Aggreko in its acquisition of General Electric's GE Energy Rentals business.
  • Carlyle in its $2.1 billion going private acquisition, with the company’s controlling shareholders, of Insight Communications.
  • Cogentrix Energy in its $2.4 billion sale to The Goldman Sachs Group.